Purpose To evaluate intravitreal conbercept injection for treatment of macular oedema secondary to central retinal vein occlusion (CRVO) in Chinese patients during 1-year follow-up in the real-world setting. Methods Twenty-seven eyes of 27 patients with macular oedema associated with CRVO were retrospectively reviewed. The eyes received monthly intravitreal conbercept injection (0.5 mg in 50 mu l) for 3 months. From then on, the patients were followed up every month and received injection pro re nata (PRN) up to 12 months. The primary outcome measurements included changes of best-corrected visual acuity (BCVA) and central retinal thickness (CRT) from baseline to month 3 and month 12. Other outcome measurements included proportion of patients gaining >= 15 letters in BCVA at month 3 and 12, the mean number of injections and safety concerns. Results The mean BCVA gain from baseline was 12.7 +/- 7.6 letters at month 3 and 14.8 +/- 9.6 letters at month 12. The mean CRT reduction from baseline was 374.5 +/- 280.7 mu m at month 3 and 428.2 +/- 241.3 mu m at month 12. The proportion of patients who gained >= 15 letters in BCVA was 45.1% at month 3 and 52.9% at month 12. The mean number of injections was 7.6 +/- 1.5. No severe local and systemic complications occurred following injection. Conclusions Intravitreal conbercept injection by three monthly loading doses followed by PRN treatment regimen was safe and efficacious for patients with macular oedema secondary to CRVO through 1-year follow-up.